PharmaCyte Biotech’s $15 Million Follow-On Public Offering

Troutman Pepper Hamilton Sanders advised PharmaCyte Biotech, Inc. on the deal.PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here
Martina Bellini

Author: Martina Bellini

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here